Argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options. The path to pioneer innovations and … At argenx, our commitment to esg is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company. · argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. · argenx se (euronext & nasdaq: At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and … To evaluate real-world utilization of oral corticosteroids (ocs) among patients with generalized myasthenia gravis (gmg) over the first 6 months post-efgartigimod … · argenx stories see where we started — and where we’re going — as we chart a new course together in immunology. This single-centre study … · about argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. At argenx, we are redefining how a biotech company can advance science and deliver innovative treatments. Our franchise-focused approach to … Were enabling new ways of working with partners, patients and each other. Argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the … To evaluate real-world utilization patterns of intravenous immunoglobulin (ivig) among patients with generalized myasthenia gravis (gmg) over 3 years post-ivig initiation. · “generalized myasthenia gravis imposes a significant lifestyle and treatment burden on patients, families, and the overall healthcare system. At argenx, we are united in our commitment to improve the lives of patients by translating immunology innovations into transformative medicines. · on , we transferred the legal ownership of all intellectual property rights of argenx se to argenx bv, effective retroactively as of. · neurological toxicities such as myasthenia gravis (mg) with or without myositis are rare but are associated with high morbidity and mortality.